Real-time PCR assay for rapid detection of clarithromycin-resistant Helicobacter pylori in gastric biopsy specimens;Schneller nachweis von clarithromycinresistenten Helicobacter pylori in der magenbiopsie mittels real-time-PCR

Zeitschrift fur Gastroenterologie

Volumn 42, Issue 12, 2004, Pages 1371-1375

  Regnath, Thomas ^a   Enninger, A ^b   Schalasta, C ^a  

^a Labor Enders und Partner   (Germany)

^b Olgahospital   (Germany)

Author keywords

Biopsy specimen; Clarithromycin; Drug resistance; Helicobacter pylori; Point mutation; Polymerase chain reaction

Indexed keywords

CARBON 13; CLARITHROMYCIN; UREA;

ACCURACY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; DEVICE; DIAGNOSTIC VALUE; ERADICATION THERAPY; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; NONHUMAN; POINT MUTATION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STOMACH BIOPSY; TREATMENT FAILURE; UREA BREATH TEST;

ADULT; ANTI-BACTERIAL AGENTS; BIOPSY; CHILD; COMPUTER SYSTEMS; DRUG RESISTANCE, MICROBIAL; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICROBIAL SENSITIVITY TESTS; POINT MUTATION; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS;

EID: 11144305029     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-813313     Document Type: Article

References (12)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347 (15): 1175-1186
2. Malfertheiner P, Megraud F, O'Morain C et al. European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection - the Maastricht 2 - 2000 Consensus Report. Aliment Pharmacol Ther 2002; 16 (2): 167-180
3. Megraud F, Lehn N, Lind T et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999; 43 (11): 2747-2752
4. Heep M, Kist M, Strobel S et al. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000; 19 (7): 538-541
5. Brautet N, Tchamgoue S, Pereira E et al. Risk factors for failure of Helicobacter pylori therapy-results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003; 17 (1): 99-109
6. Houben MH, van de Beek D, Hensen EF et al. A systematic review of Helicobacter pylori eradication therapy-the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999; 13 (8): 1047-1055
7. Versalovic J, Osato MS, Spakovsky K et al. Point mutations in the 23SrRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J of Antimicrobial Chemotherapy 1997; 40: 283-286
8. Alarcon T, Domingo D, Prieto N et al. PCR using 3′-mismatched primers to detect A2142C mutation in 23S rRNA conferring resistance to clarithromycin in Helicobacter pylori clinical isolates. J Clin Microbiol 2000; 38: 923-925
9. Matsumura M, Hikiba Y, Ogura K et al. Rapid detection of mutations in the 23SrRNA gene of Helicobacter pylori that confers resistance to clarithromycin treatment to the bacterium. J Clin Microbiol 2001; 39: 691-695
10. Oleastro M, Ménard A, Santos A et al. Real-Time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori. J Clin Microbiol 2003; 41: 397-402
11. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing (13th informational supplement) NCCLS document number M100-S13 (M7), Wayne, PA: NCCLS, 2003
12. Romano M, Marmo R, Cuomo A et al. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. Clin Gastroenterol Hepatol 2003; 1 (4): 273-278